ReviewFrontiers in immunology2025
Lymphoepithelioma-like carcinoma with carcinosarcoma of the endometrium: a case report and literature review.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report describes a 56-year-old female diagnosed with lymphoepithelioma-like carcinoma with carcinosarcoma of the endometrium (LELCCSE). She experienced vaginal bleeding and lower abdominal discomfort without any obvious cause following six years of menopause. She sought treatment at our hospital in Hangzhou, China. An ultrasound examination revealed a hypoechoic mass within the uterus. Subsequently, a biopsy confirmed it as lymphoepithelioma-like carcinoma (LELC) with carcinosarcoma.The patient underwent a total hysterectomy, bilateral salpingo-oophorectomy, and associated lymphadenectomy. The postoperative pathology suggested LELC complicated with carcinosarcoma and an IIC grade by the 2023 FIGO staging system. She received adjuvant chemotherapy and radiotherapy without any molecular testing due to her financial constraints. A gene which encodes the catalytic subunit of DNA polymerase epsilon(POLE) mutation was found by the retrospective molecular testing; however, no recurrence or metastasis occurred after 12 follow-up months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.